secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001790340-24-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104
----------------------------------------------------------------------------

- Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.
- Positive initial Phase 2a data: complete and partial responses with IMM-1-104 + chemo in first-line pancreatic cancer.
- FDA granted Orphan Drug and Fast Track designations for IMM-1-104 in pancreatic cancer.
- Cash runway into Q4 2025; R&D expenses $11.3M, G&A $4.0M.
- Initial data from additional Phase 2a arm and Phase 1 data for IMM-6-415 expected by year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/0001790340-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034024000078/imrx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001790340-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer